OSAKA -- Ono Pharmaceutical has redeployed a significant portion of its sales force to the cancer battlefront to promote a new cancer immunity drug.
Rather than attacking cancer directly, Opdivo is an antibody that works by enhancing the ability of the immune system to recognize and attack cancer cells. It was approved in Japan for the treatment of melanoma in 2014, and also for lung cancer this past December.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
to learn how you can update your cookie settings.